$艾伯维公司(ABBV)$表示,终止ABBV-154的开发工作。 TNFα-新型糖皮质激素受体调节剂。还是安全性/副作用方面的考量。 it did exactly what we thought it would do from the standpoint of efficacy,” AbbVie CEO Rick Gonzalez said during the first-quarter earnings call. “But it did it in a way onl...